Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...

Richard F. Ludueña, Professor Emeritus at the University of Texas Health San Antonio, discusses his innovative approach to ...

Researchers from Qingdao University described the discovery and preclinical characterization of a novel series of tubulin polymerization inhibitors that led to the identification of [I] as the most ...